Alcon launches Hydrus Microstent in India to transform glaucoma care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Germany will be the first launch market
Subscribe To Our Newsletter & Stay Updated